Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.
Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.
复制标题
DOI：
10.3892/or.16.3.533
复制
发表时间：
2006-09
期刊：
影响因子：
4.2
通讯作者：
K. Endo;H. Sasaki;M. Yano;Y. Kobayashi;H. Yukiue;H. Haneda;E. Suzuki;O. Kawano;Y. Fujii
中科院分区：
文献类型：
--
作者：
K. Endo;H. Sasaki;M. Yano;Y. Kobayashi;H. Yukiue;H. Haneda;E. Suzuki;O. Kawano;Y. Fujii
一些研究表明，表皮生长因子受体（EGFR）基因突变，EGFR基因扩增，和其他一些生物标志物可能是吉非替尼敏感性的预测因子。我们分析了22例吉非替尼治疗的非小细胞肺癌（NSCLC）患者的EGFR突变和EGFR拷贝数及其与患者生存的关系。我们还研究了143例吉非替尼初治的日本NSCLC病例。还在59例吉非替尼初治NSCLC病例中研究了erbB2拷贝数。在接受吉非替尼治疗的患者中，EGFR突变的存在与吉非替尼的更高应答率和更长的总生存期相关，但EGFR基因拷贝数的增加与此无关。在吉非替尼初治病例中，EGFR突变而非EGFR基因拷贝数与性别、病理亚型和吸烟状态显著相关。59例患者的erbB 2拷贝数与EGFR突变或EGFR拷贝数无明显相关性。总之，与EGFR基因拷贝数相比，EGFR突变是吉非替尼治疗患者临床结局的更好预测因子。
Several studies have suggested that epidermal growth factor receptor (EGFR) gene mutation, EGFR gene amplification, and some other biomarkers may be predictors of gefitinib sensitivity. We analyzed EGFR mutation and EGFR copy number in 22 gefitinib-treated non-small cell lung cancer (NSCLC) cases and their relation to the survival of patients. We also studied 143 gefitinib-naïve Japanese NSCLC cases. The erbB2 copy number was also studied in 59 gefitinib-naïve NSCLC cases. In gefitinib-treated patients, the presence of EGFR mutation was associated with a higher response rate to gefitinib and a longer overall survival, but the increased EGFR gene copy number was not. In gefitinib-naïve cases, EGFR mutation but not EGFR gene copy number was significantly correlated with gender, pathological subtypes, and smoking status. The erbB2 copy number was not significantly correlated with the EGFR mutation or EGFR copy number in 59 cases. In conclusion, EGFR mutation was a better predictor of clinical outcome in gefitinib-treated patients than the EGFR gene copy number.